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Objectives The purpose of this study was to evaluate the impact of myocardial viability assessment by delayed-enhanced
cardiac magnetic resonance (DE-CMR) and of revascularization therapy on survival in patients with coronary ar-
tery disease (CAD) and low ejection fraction (EF).
Background Prior studies have shown that DE-CMR predicts recovery of left ventricular (LV) dysfunction after revascularization.
Methods The authors prospectively evaluated survival of 144 consecutive patients (130 males, age 65  11 years) with
CAD and LV dysfunction (EF: 24  7%) undergoing DE-CMR. Eighty-six patients underwent complete revascular-
ization of dysfunctional myocardium (79 coronary artery bypass grafting, 7 percutaneous coronary intervention),
whereas 58 patients remained under medical treatment.
Results Over the 3-year median follow-up, 49 patients died. Three-year survival was significantly worse in medically
treated patients with dysfunctional viable than with nonviable myocardium (48% vs. 77% survival, p  0.02). By
contrast, in revascularized patients, survival was similar whether myocardium was viable or not (88% and 71%
survival, respectively, p  NS). Hazard of death of viable myocardium remaining under medical treatment versus
complete revascularization was 4.56 (95% confidence interval [CI]: 1.93 to 10.8). Cox multivariate analysis indi-
cated that interaction of revascularization and viability provided significant additional value (chi-square test 
13.1, p  0.004) to baseline predictors of survival (New York Heart Association functional class, wall motion
score, and peripheral artery disease). More importantly, in 43 pairs of propensity score–matched patients, haz-
ard of death (hazard ratio: 2.5 [95% CI: 1.1 to 6.1], p  0.02) remained significantly higher for medically treated
patients rather than for those with fully revascularized viable myocardium.
Conclusions Without revascularization, presence of dysfunctional viable myocardium by DE-CMR is an independent predictor of mortality
in patients with ischemic LV dysfunction. This observation may be useful for pre-operative selection of patients for
revascularization. (J Am Coll Cardiol 2012;59:825–35) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.073Delayed-enhancement (DE) cardiac magnetic resonance
(CMR) detects replacement of normal viable myocytes by
necrosis or fibrosis with high spatial resolution, and excellent
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become a preferred method for assessment of structural
changes in ischemic and nonischemic cardiomyopathies (2).
Several studies have demonstrated that DE-CMR can predict
myocardial viability in coronary artery disease (CAD) (3–7).
See page 836
Indeed, they showed that dysfunctional segments with DE,
corresponding to infarcted nonviable myocardium, do not im-
prove in function after revascularization, whereas dysfunctional
myocardium without DE, and thus without necrosis and suppos-
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cularization and contribute to in-
crease left ventricular (LV) ejection
fraction (EF).
Yet, the impact of DE-CMR
viability assessment on prognosis
remains incompletely under-
stood. Several reports (8–12) in-
dicated that the presence of DE
by CMR, i.e., nonviable myocar-
dium, predicts increased risk in
patients with and without CAD,
but did not evaluate the potential
benefit of revascularization on
survival. Moreover, these studies
conflict with earlier work using
nuclear or stress echocardiogra-
phy imaging (13), which showed
that viable rather than nonviable
myocardium is associated with
poor prognosis, whenever patients are treated medically.
We hypothesized that the presence or absence of myo-
cardial viability detected by DE-CMR might affect survival
differently in patients undergoing revascularization versus
medical treatment. Accordingly, we evaluated survival of
CAD patients with EF 35% stratified according to pres-
nce or absence of DE by CMR in dysfunctional segments
nd to revascularization therapy. We used Cox survival
nalysis to assess whether the interaction of myocardial
iability by DE-CMR with revascularization therapy pro-
ides independent prognostic information over baseline
linical, hemodynamic, and angiographic data. We also used
ropensity score matching to assess survival corrected for
otential differences of treatment strategies.
aterials and Methods
atient population. We evaluated survival of consecutive
atients undergoing DE-CMR for assessment of myocar-
ial viability between January 1, 2002, and December 31,
009. In the present study, we only considered patients with
AD whose LVEF was 35% by CMR, who satisfied
elker’s criteria for ischemic cardiomyopathy (14), i.e.,
aving either 70% luminal diameter stenosis of the prox-
mal left anterior descending coronary artery or multivessel
isease of proximal coronary arteries, and who had not been
evascularized. Accordingly, we excluded patients with non-
schemic cardiomyopathy or without cardiac catheterization
ithin 3 months before CMR, patients with significant
alve disease (grade 2 mitral or aortic insufficiency or
ignificant mitral or aortic stenosis), and all patients who
ad already been revascularized at the time of the study. We
lso excluded patients who had a life expectancy 1 year
ecause of other comorbidities and patients with infarct
omplications. One hundred forty-four patients satisfied the
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
CI  confidence interval
CMR  cardiac magnetic
resonance
DE  delayed enhancement
EF  low ejection fraction
HR  hazard ratio
LV  left ventricular
MI  myocardial infarction
NYHA  New York Heart
Association
PCI  percutaneous
coronary interventionnclusion criteria (Fig. 1) and constituted the final study oopulation. All participants gave informed consent to par-
icipate in this institutional review board–approved study.
ardiac magnetic resonance. All patients underwent a
tandardized CMR protocol for myocardial viability on a
.5-T scanner (Intera CV, Philips Medical Systems, Best,
he Netherlands) as described previously (7). Briefly, 10 to
2 consecutive short-axis images covering the entire left
entricle and, respectively, one 2-, 3-, and 4-chamber
ong-axis cine SSFP images were acquired for assessment of
yocardial function. Ten to 15 min after injection of 0.2
mol/kg gadolinium-based contrast, identical prescriptions
f short- and long-axis slices were acquired using a
-dimensional- or 3-dimensional inversion recovery se-
uence allowing for the assessment of myocardial viability.
CMR images were analyzed on a commercial workstation
Viewforum 4.1, Philips Medical Systems, Best, the Neth-
rlands). LV volumes and EF were obtained by manual
racing of contours on the short-axis images in end-diastole
nd end-systole. Regional wall motion was graded visually
y consensus of 2 reviewers blinded to follow-up data on a
-level Likert scale (1: normal contraction, 2: hypokinesia,
: akinesia) using a standard 17-segment American Heart
ssociation model. Transmurality of DE was determined
isually by the same readers on a 5-point Likert scale
0: absent, 1: 1% to 25% transmurality, 2: 26% to 50%
ransmurality, 3: 51% to 75% transmurality, 4: 76% to 100%
ransmurality) in the same segments. A dysfunctional segment
wall motion score 2) was considered viable when transmu-
ality was50%. Overall wall motion and transmurality score,
nd number of dysfunctional viable segments were reported per
atient. According to Bax et al. (15), a patient was considered
o have viable myocardium when 4 dysfunctional segments
ere viable (transmurality of DE 50%).
ollow-up. Survival status was obtained by phone contact
ith the patients, their relatives, or their physicians. Pa-
ient’s history and treatment was retrieved from medical files
nd from review of visit or hospital records. The cause of
eath was categorized as cardiac or noncardiac. Cardiac
eath was defined as death attributable to congestive heart
ailure (i.e., death preceded by acute worsening or exacer-
ation of heart failure), myocardial infarction (MI), sudden
eath (i.e., unexpected, unwitnessed, or witnessed death in
bsence of other apparent causes), or occurring after cardiac
evascularization procedure. Heart transplantation was
ensored.
tatistical methods. Statistical analyses were performed
sing SPSS version 15 (SPSS Corp., Somers, New York)
nd STATA version 11 (Stata Corp. LP, College Station,
exas) software. All tests were 2-sided, and a p value 0.05
as considered statistically significant. Continuous variables
ere expressed as mean  1 SD, categorical variables as
ounts and percentages. Hazard ratios (HR) were expressed
s mean and 95% confidence intervals (CIs). Baseline
haracteristics of patients undergoing revascularization ver-
us medical treatment were compared using chi-square test
r unpaired t test. Survival in revascularized patients with or
827JACC Vol. 59, No. 9, 2012 Gerber et al.
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Meier method and the Mantel-Cox test. The index date was
the date of the CMR. The primary endpoint was all-cause
death. The secondary endpoint was cardiovascular mortality.
All clinical parameters were proposed for inclusion in a
univariate Cox proportional hazard model. To assess the
potential additive prognostic value of revascularization and
myocardial viability over and beyond other predictors of mor-
tality, we computed a backward stepwise multivariate Cox
model from all significant (p  0.10) univariate correlates of
survival excluding revascularization and viability. We then
evaluated the ability of myocardial viability and revasculariza-
tion treatment to improve the prediction of death of this
baseline model by comparing the additional increase of the
chi-square value of the combined model over the baseline
model using the log-likelihood test. Two different models were
tested, evaluating the additional value of the number of
dysfunctional viable segments as continuous variables (Model
1), or the binary presence or absence of viability (4 dysfunc-
tional segments) (Model 2), and their respective interaction
with revascularization therapy. Relative HRs for each specific
Figure 1 Selection of the Study Population
CAD  coronary artery disease; DE-CMR  delayed-enhancement cardiac magneticovariate of the final models were computed as the exponent ofthe regression coefficient. The total HR in each patient was
calculated as the product of all relative HRs.
To reduce the effect of treatment selection bias and to
balance observed differences between revascularized and med-
ically treated patients, we also performed a propensity score
analysis. The propensity scores were obtained using a binary
logistic regression model where treatment was the dependent
variable, and significant correlates of the therapeutic decision
acted as independent variables. The computed propensity score
included 6 variables (New York Heart Association [NYHA]
functional class, number of diseased coronary arteries, history
of infarction, atrial fibrillation, wall motion score, and number
of dysfunctional viable segments) and had an area under the
curve of 0.80 (p  0.001) to predict treatment. We then
selected pairs of patients in the 2 treatment groups (1:1 match)
using a nearest-neighbor matching algorithm within a caliper
of 0.25 SD of the propensity score, using the psmatch2 routine
within STATA. Overall survival in the matched treatment
groups according to presence or absence of myocardial viability
was then compared using the Kaplan-Meier method. The
propensity score was also entered together with the therapeutic
nance; EF  ejection fraction; LV  left ventricular.c resoand the myocardial viability into a Cox proportional hazards
n828 Gerber et al. JACC Vol. 59, No. 9, 2012
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adjusted HR associated with the therapeutic decision.
Results
Study population and treatment. Table 1 shows charac-
teristics of the study population. After CMR, 79 patients
underwent coronary artery bypass graft (CABG) within a
median of 7 days, and 19 underwent percutaneous coronary
intervention (PCI) within a median of 3 days. Eighty-six
revascularization procedures (all CABG and 7 PCI) were
considered complete, fully revascularizing all diseased ves-
sels and dysfunctional segments. Twelve patients had in-
complete PCI procedures, revascularizing only nondysfunc-
tional myocardium. Although all patients had CAD suitable
for revascularization therapy, 46 remained under medical
treatment, the decision taking into account risks and clinical
Characteristics of the Patient PopulationTable 1 Characteristics of the Patient Population
All
(N  144)
Fully Reva
(n 
Demographics Age, yrs 65 11 65
Male/female 130/14 75
Clinical history Prior MI 93 (65%) 49 (5
Risk factors Hypertension 93 (65%) 55 (6
Current smoker 16 (11%) 8 (9
Former smoker 70 (49%) 42 (4
Hyperlipidemia 80 (56%) 46 (5
Family history of CAD 47 (33%) 26 (3
Diabetes 49 (34%) 28 (3
Symptoms CCS class 0 93 (64%) 51 (5
CCS class 1–2 24 (17%) 16 (1
CCS class 3–4 27 (19%) 19 (2
NYHA functional class 1–2 59 (41%) 43 (5
NYHA functional class 3–4 85 (59%) 43 (5
ECG Q-wave 75 (52%) 41 (4
LBBB 13 (9%) 9 (1
AF 19 (14%) 8 (9
Angiography 1 vessel 11 (8%) 8 (9
2 vessels 38 (26%) 13 (1
3 vessels 95 (66%) 65 (7
Comorbidity PAD 26 (18%) 15 (1
Prior stroke 15 (10%) 7 (8
COPD gold II 14 (10%) 10 (1
PHT 60 mm Hg 13 (9%) 5 (6
GFR, ml/min/m2 78 35 76
EuroSCORE Additive 5 2 5
Logistic 8 7 7
MR EF 24 7 24
EDVi, ml/m2 141 42 138
ESVi, ml/m2 108 39 106
Dysfunctional 12 4 12
Average WMS 36 5 36
Dysfunctional viable segments 8 5 9
Average transmurality 20 13 15
Values are mean  SD, n, or n (%).
AF  atrial fibrillation; CAD  coronary artery disease; CCS  Canadian Cardiac Society angina
EDVi  indexed end-diastolic volume; ESVi  indexed systolic volume; GFR  glomerular filtrati
onsignificant; NYHA  New York Heart Association functional class; PAD  peripheral arterial disease;
score.status, including 10 patients who refused CABG. Six
medically treated patients (1 with viable, 5 with nonviable
myocardium) received an implantable cardioverter-defibrillator.
One medically treated patient and 1 patient after CABG
underwent cardiac resynchronization therapy. Patients
undergoing complete revascularization had a similar age,
CAD risk factors, comorbidities, LV volumes, EF, and
surgical risk by EuroSCORE than medically treated or
incompletely revascularized patients. However, medically
treated or incompletely revascularized patients had higher
NYHA functional class, greater proportion of 2- rather
than 3-vessel disease, more prevalence of myocardial
infarcts, higher transmurality of DE, and less dysfunc-
tional viable segments by CMR than fully revascularized
patients. There was also a nonsignificant trend for higher
prevalence of pulmonary hypertension and atrial fibrilla-
ized Incomplete PCI
(n  12)
Remaining Under Medical Treatment
(n  46) p Value
66 9 63 1 2 0.45 (NS)
12/0 43/3 0.37 (NS)
8 (67%) 36 (78%) 0.05
10 (83%) 28 (61%) 0.37 (NS)
1 (8%) 7 (15%) 0.73 (NS)
4 (33%) 24 (52%) 0.50 (NS)
7 (58%) 27 (59%) 0.28 (NS)
4 (33%) 17 (37%) 0.76 (NS)
6 (50%) 15 (33%) 0.52 (NS)
4 (33%) 38 (82%)
3 (25%) 5 (11%) 0.008
5 (42%) 3 (6%)
4 (33%) 12 (26%)
8 (66%) 34 (74%) 0.25
8 (67%) 26 (56%) 0.36 (NS)
2 (17%) 2 (4%) 0.26 (NS)
4 (33%) 7 (15%) 0.06 (NS)
0 (0%) 3 (6%)
5 (42%) 20 (43%) 0.003
7 (58%) 23 (50%)
4 (33%) 7 (15%) 0.35 (NS)
1 (8%) 7 (15%) 0.39 (NS)
0 (0%) 4 (8%) 0.63 (NS)
1 (8%) 7 (15%) 0.18 (NS)
88 52 80 34 0.43 (NS)
5 3 5 2 0.61 (NS)
10 10 8 8 0.58 (NS)
23 9 23 7 0.48 (NS)
131 21 149 44 0.25 (NS)
102 27 115 41 0.34 (NS)
12 3 11 3 0.14 (NS)
38 5 37 5 0.89 (NS)
6 5 6 5 0.001
27 12 27 12 0.001
OPD  chronic obstructive pulmonary disease; ECG  electrocardiogram; EF  ejection fraction;
; LBBB  left bundle branch block; MI  myocardial infarct; MR  magnetic resonance; NS scular
86)
 10
/11
8%)
5%)
%)
9%)
4%)
1%)
3%)
9%)
9%)
2%)
0%)
0%)
8%)
1%)
%)
%)
5%)
6%)
7%)
%)
2%)
%)
 30
 2
 7
 7
 42
 40
 4
 5
 5
 11
score; C
on ratePCI  percutaneous coronary intervention; PHT  pulmonary hypertension; WMS  wall motion
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larized patients.
Events at follow-up. Follow-up was 100% complete for a
median duration of 3 years. During follow-up, 49 patients
died, 40 of cardiovascular causes: 7 postoperatively, 17 of
heart failure, 12 suddenly, 3 of stroke, and 1 of vascular
cause. Six patients developed worsening heart failure (5
patients under medical treatment and 1 after CABG)
requiring heart transplantation. One patient with an im-
plantable cardioverter-defibrillator died after 405 days of
worsening heart failure, another underwent heart transplan-
tation. Both had nonviable myocardium. No shocks oc-
curred during follow-up.
Survival according to treatment and myocardial viability.
To assess the potential prognostic value of myocardial
viability by DE-CMR and its interaction with revascular-
ization on long-term survival, the study population was
divided into several subgroups (Fig. 2): 1) patients with
completely revascularized viable myocardium (n  68);
2) patients with viable myocardium undergoing incomplete
revascularization not including the dysfunctional region
(n  7); 3) patients with viable myocardium remaining
under medical treatment (n  26); 4) patients with com-
letely revascularized nonviable myocardium (n  18);
) patients with nonviable myocardium remaining under
Figure 2 Kaplan-Meier Survival Curves Comparing Overall 3-Yea
According to Treatment and Presence of Myocardial V
Survival was significantly worse in patients with dysfunctional viable myocardium r
including dysfunctional myocardium than in other subgroups. CR  complete revas
M  medical treatment; NV  nonviable myocardium; R/  remaining under mededical treatment (n  20); and 6) patients undergoing
ncomplete revascularization not including the dysfunc-
ional nonviable myocardium (n  5). Figure 2 shows
hat the 3-year overall survival was significantly worse in
he subgroups of patients with dysfunctional viable myo-
ardium remaining under medical treatment (46%) or
ndergoing incomplete revascularization (54%) than in
ncompletely revascularized (100%) or medically treated
atients without viable myocardium (77%), and in com-
letely revascularized patients with and without dysfunc-
ional viable myocardium (83% and 71% for the com-
letely revascularized viable and nonviable myocardium
ubgroups, respectively).
Because survival in patients undergoing incomplete re-
ascularization not including the dysfunctional myocardium
as similar to that of patients remaining under medical
reatment alone, and because the objective of our study was
o evaluate the impact of revascularization of dysfunctional
yocardium, patients with incomplete revascularization not
ncluding dysfunctional myocardium were merged with the
roup of medically treated patients for further analysis
Figs. 3A and 3B). Figure 4 shows that 3-year HR of death
n patients with viable myocardium (4 viable segments)
as significantly higher (4.56) when they remained under
edical treatment or when revascularization did not include
rvival in Subgroups of Patients
ity in Dysfunctional Myocardium
ng under medical treatment or undergoing incomplete revascularization not
zation; IR  incomplete revascularization not including dysfunctional region;
atment; V  viable myocardium.r Su
iabil
emaini
culari
ical tre
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myocardium was completely revascularized. By contrast, in
patients without viable myocardium, there was no benefit of
revascularization therapy on survival.
Cox proportional hazard analysis of survival. Univariate
predictors of overall survival in our patient population are
shown in Table 2. Table 3 demonstrates that the interaction
Figure 3 Kaplan-Meier Survival Curves Comparing Overall and C
According to Treatment and Presence of Myocardial V
Overall (A) and cardiovascular (B) 3-year survival were significantly worse in patien
or undergoing incomplete revascularization not including dysfunctional regions. Abbetween viability, both as continuous variable (number of dys-functional viable segments—Model 1) and on per patient basis
(4 dysfunctional viable segments per patient—Model 2), and
treatment had significant additional value to improve the
prediction of death over all baseline clinical parameters.
Propensity score–matched analysis. Propensity score
matching selected 43 matched pairs of patients with iden-
tical characteristics undergoing complete revascularization,
vascular 3-Year Survival
ity in Dysfunctional Myocardium
h viable myocardium who remained under medical treatment
ions as in Figure 2.ardio
iabil
ts wit
breviator remaining under medical treatment or undergoing in-
m
v
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were no significant differences for any of the covariates
between the 2 groups of patients. Kaplan-Meier survival
curves constructed for these 43 pairs of propensity score–
matched patients showed a persistent significant risk of
overall and cardiovascular death in medically treated or
incompletely revascularized patients with viable myocar-
dium (Figs. 5A and 5B).
Also, when the propensity score was entered into a Cox
odel, medical treatment in the presence of myocardial
iability (HR: 2.5; 95% CI: [1.1 to 6.1]; p  0.02) and the
interaction of revascularization treatment with the number
of dysfunctional viable segments still provided additional
prognostic value (additional chi-square test: 5.14, p  0.02)
over and above the propensity score alone.
Discussion
The salient findings of our study were that the interaction
between presence of myocardial viability by DE-CMR and
revascularization significantly predicted survival in CAD
patients with low EF. Indeed, overall survival was signifi-
cantly worse when dysfunctional viable myocardium was not
revascularized than when it was completely revascularized.
By contrast, we observed no significant difference in survival
Figure 4 Hazard Ratio of Risk of 3-Year Death According to Pre
Patients with dysfunctional viable myocardium had a 4.56 higher risk of death whe
not including the dysfunctional myocardium. CI  confidence interval; R/  remain
Cox Univariate Analysis of Parameters Significantly Associated WitTable 2 Cox Univariate Analysis of Parameters Significantly As
Parameters
PAD
Creatinine clearance
NYHA functional class III/IV
EF
EuroSCORE logistic
EuroSCORE additive
Wall motion score
Dysfunctional viable segments per patient (continuous variable)
Medical treatment or incomplete vs. complete revascularization
Revascularization  dysfunctional viable segments per patient (continuous variable
Medical treatment or incomplete revascularization and presence of viable myocardi
(4 dysfunctional viable segments per patient)  interaction between 2 factors; CI  confidence interval; HR  hazard ratio; other abbreviations as iin patients with nonviable myocardium whether they un-
derwent revascularization or not.
Several studies have evaluated the value of DE-CMR to
predict outcomes (8–12) and reported that presence of DE
identifies patients with higher risk of events. At first sight,
this appears to conflict with the results of our data, where we
observed that viable myocardium, i.e., dysfunctional regions
showing absence or 50% transmurality of DE was asso-
ciated with worse survival, when such viable myocardium
was not revascularized. However, these apparent discrepan-
cies likely reflect differences in study design and patient
populations, in particular with respect to the presence of
CAD and revascularization therapy. Indeed, some studies
that demonstrated that DE-CMR predicts worse outcomes
were performed in unselected patients with unknown CAD
status (8–10). In this setting, the identification of DE by
CMR likely detects patients with CAD from those with
nonischemic cardiomyopathies, which are known to have
better outcomes. Other works were performed in patients
with acute reperfused ST-segment elevation MI (16–18),
demonstrating that infarct size measured by DE-CMR is
a stronger predictor of events than EF. This likely occurs
because in revascularized acute MI, the extent of myo-
cardial injury may be overestimated by EF at the time of
e or Absence of Viability and Treatment
aining under medical treatment, or when revascularization was incomplete,
der medical treatment.
k of Overall 3-Year Mortalityted With Risk of Overall 3-Year Mortality
HR (95% CI) Chi-Square p Value
2.29 (1.57–3.34) 4.81 0.03
0.986 (0.979–0.993) 5.15 0.04
4.79 (2.61–8.82) 7.72 0.01
0.955 (0.933–0.977) 4.00 0.04
1.057 (1.037–1.077) 5.50 0.003
1.170 (1.083–1.265) 4.08 0.04
1.085 (1.050–1.120) 6.05 0.01
0.996 (0.964–1.028) 0.02 0.88
2.05 (1.45–2.89) 4.30 0.04
1.09 (1.06–1.13) 7.69 0.005
3.77 (2.51–5.69) 12.51 0.001senc
n rem
ing unh Rissocia
)
umn Table 1.
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myocardium may be acutely stunned and spontaneously re-
cover function over time. Yet, final EF, LV volumes, and
post-MI remodeling, which are important predictors of out-
comes in patients with acute MI, are well known to be
predicted by the extent of irreversible injury as measured by
initial infarct size (16,19).
So far, only a few studies have been performed to assess the
potential value of myocardial viability by CMR in patients with
chronic nonrevascularized CAD (11,12). Kwon et al. (11)
demonstrated in 349 patients with similar severe reduction of
EF as in our study (mean EF: 24%), of presumed ischemic
etiology (history of MI, of coronary revascularization, or
presence of at least 1 epicardial coronary vessel stenosis) that
more events occurred when patients had higher extent and
transmurality of scar by DE-CMR. However, coronary an-
giography was not systematically performed, and the patient
population was heterogeneous with respect to whether CAD
was still present or had been revascularized at the time of the
study. An important aspect, which also may explain different
results, is that in the prior studies, viability was not determined
in relation to regional dysfunction. Indeed, these studies
evaluated the magnitude of DE in the entire heart, rather than
assessing presence or absence of DE in dysfunctional segments.
Finally, none of the prior works evaluated the influence of
revascularization of dysfunctional myocardium on outcomes.
Our study is the first to our knowledge to specifically examine
the question whether revascularization of dysfunctional but
viable myocardium detected by DE-CMR is associated with
different outcomes.
The findings of the present study are in agreement with
earlier work performed using dobutamine echocardiogra-
phy, positron emission tomography, and conventional nu-
clear imaging, which demonstrated that patients with dys-
functional but viable myocardium have better outcomes
Additional Prognostic Value of Myocardial Viability and RevascularTable 3 Additional Prognostic Value of Myocardial Viability and
Parameters
NYHA functional class
Wall motion score
PAD
Combined baseline model
Model 1 (# of dysfunctional viable segments used as continuous variable)
Revascularization of dysfunctional segments
Absolute # of dysfunctional viable segments
Revascularization  absolute # of dysfunctional viable segments
Additional value of Model 1 to baseline model
Model 2 (viability defined 4 dysfunctional viable segments/patient)
Medical treatment and viable myocardium
(presence of 4 dysfunctional viable segments)
Revascularization and nonviable myocardium
(presence of 4 dysfunctional viable dysfunctional segments)
Additional value of Model 2 to baseline model
  interaction in Cox Model; other abbreviations as in Table 1.when revascularized than when medically treated. Indeed, ina meta-analysis of these studies (13), revascularization of
dysfunctional but viable myocardium was associated with a
79% reduction of annual death rate. By contrast, and similar
to our findings, this meta-analysis reported that revascular-
ization of patients with nonviable myocardium did not
influence survival.
The observation that nonrevascularized viable myocar-
dium has worse clinical outcome is also supported by animal
studies, which reported increased arrythmogenic vulnerabil-
ity, leading to sudden cardiac death in dysfunctional, non-
revascularized viable myocardium (20,21). This is likely due
to the fact that such dysfunctional hibernating or chronically
stunned myocardium in nonrevascularized CAD is exposed
to repeated episodes of ischemia and reperfusion (22,23)
causing electrical instability due to depolarization of mem-
brane potentials. The fact that viable rather than nonviable
myocardium increases risk in CAD patients is also sup-
ported by other DE-CMR works, which indicated that the
peri-infarct zone (24,25), that is, regions where infarct is not
transmural, but where viable myocytes coexist with minute
amounts of scar, predict arrhythmic events.
Clinical implications. The long-term survival of patients
with severely depressed LV function and CAD is poor. A
major goal in the management of these patients consists to
identify those who may benefit from revascularization strat-
egies. Indeed, revascularization of dysfunctional but viable
myocardium was shown to improve LVEF and symptoms of
heart failure. Yet, surgical revascularization in patients with
poor EF is associated with significant perioperative risk. It is
therefore important to balance this operative risk with a
potential benefit in survival by reduction of further adverse
cardiac events after revascularization (26,27).
Our study suggests that similar to positron emission
tomography, dobutamine echocardiography, and nuclear
imaging, DE-CMR may be useful to predict, not only
n to Predictors of Survivalascularization to Predictors of Survival
Partial HR Chi-Square Test to Remove p Value
.59 (1.04–12.4) 4.09 0.04
.06 (0.99–1.13) 3.18 0.07
.07 (0.98–4.38) 3.68 0.05
17.10 0.004
Chi-Square Test to Enter
.54 (0.15–1.99) 0.85 0.35
.90 (0.80–1.00) 3.77 0.05
.15 (1.00–1.33) 3.88 0.05
7.56 0.05
.47 (1.50–8.01) 8.47 0.004
.93 (1.61–21.9) 7.18 0.007
13.10 0.004izatioRev
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5functional improvement of patients with CAD and LV
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revascularization of dysfunctional viable myocardium pro-
vides a significant improvement in patient outcomes versus
medical treatment. It thus suggests that patients with viable
myocardium should be revascularized to improve survival.
Also, it evokes that incomplete revascularization of nondys-
functional myocardium is not protective when dysfunctional
Figure 5 Kaplan-Meier Survival Curves Comparing Overall and C
in 43 Pairs of Propensity Score–Matched Patients
In these propensity score–matched patients, overall (A) and cardiovascular (B) 3-
myocardium who remained under medical treatment or undergoing incomplete revaviable myocardium is not revascularized. Interestingly, how-ever, this could not be confirmed in the recently published
randomized STICH (Surgical Treatment for Ischemic
Heart Failure) trial (28). Several reasons may account for
this. Even though the STICH trial enrolled patients with
roughly similar EF (mean: 28%) as our study, it included a
majority of patients with angina rather than heart failure
symptoms. Also, severity of LV dilation and of degree of
vascular 3-Year Survival
rvival remained significantly worse in patients with viable
rization not including dysfunctional regions. Abbreviations as in Figure 3.ardio
year su
sculaCAD was significantly less than in our study, resulting in
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than in our population. In addition, viability assessment was
not mandated, but at the discretion of investigators, and a
heterogeneous protocol for assessment of myocardial viabil-
ity, either dobutamine echocardiography or single-photon
emission computed tomography was used. Finally and most
importantly, the definition of myocardial viability by single-
photon emission computed tomography did not mandate
myocardial viability to be found in dysfunctional segments,
but rather required a threshold number of segments with
normal perfusion to identify patients with viability. All this
may explain the surprising negative outcome of the STICH
viability substudy.
Study limitations. As with most other works evaluating
the value of myocardial viability on survival, the present
study was not randomized, and results from CMR were not
blinded to physicians involved in treatment strategies, po-
tentially resulting in treatment selection bias. Although
most baseline characteristics were similar for patients un-
dergoing revascularization and medically treated patients,
the 2 groups differed in severity of heart failure symptoms
and the amount of myocardial viability. This might have
influenced outcomes in the groups. Therefore, we per-
formed a propensity score analysis, where we matched
revascularized and nonrevascularized patients with similar
baseline characteristics, particularly myocardial viability,
pairwise and compared survival in the different subgroups.
Because both types of analysis demonstrated significant
additional prognostic value of the interaction of myocardial
viability and revascularization, we believe that these param-
eters may not have played a major confounding factor in the
present study.
Conclusions
Our data clearly indicate that patients with severe LV
dysfunction of ischemic etiology, who remain under medical
treatment despite the presence of myocardial viability de-
tected by DE-CMR, incur significant excess of mortality.
These observations may be useful to determine which
patients with impaired LV function are most likely to
benefit from revascularization therapies.
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